CONTEXT THERAPEUT.DL-001
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the developm… Read more
CONTEXT THERAPEUT.DL-001 (6K9) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, CONTEXT THERAPEUT.DL-001 (6K9) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CONTEXT THERAPEUT.DL-001 - Net Assets Trend (None–None)
This chart illustrates how CONTEXT THERAPEUT.DL-001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CONTEXT THERAPEUT.DL-001 (None–None)
The table below shows the annual net assets of CONTEXT THERAPEUT.DL-001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to CONTEXT THERAPEUT.DL-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
CONTEXT THERAPEUT.DL-001 Competitors by Market Cap
The table below lists competitors of CONTEXT THERAPEUT.DL-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zinus Inc
KO:013890
|
$98.06 Million |
|
Anteris Technologies Ltd
PINK:AMEUF
|
$98.07 Million |
|
EUROCELL (WI) LS -001
F:6YQ
|
$98.11 Million |
|
RYVU THERAPEUTICS ZY-40
F:9Y4
|
$98.16 Million |
|
Sphera Franchise Group SA MiFID Eligible Security
RO:SFG
|
$98.03 Million |
|
Calfrac Well Services Ltd
PINK:CFWFF
|
$97.96 Million |
|
Freightcar America Inc
NASDAQ:RAIL
|
$97.96 Million |
|
Sotkamo Silver AB
HE:SOSI1
|
$97.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CONTEXT THERAPEUT.DL-001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares CONTEXT THERAPEUT.DL-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently CONTEXT THERAPEUT.DL-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares CONTEXT THERAPEUT.DL-001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,345,847,517
- Average return on equity (ROE) among peers: -601.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CONTEXT THERAPEUT.DL-001 (6K9) | €- | N/A | N/A | $98.04 Million |
| 09R (09R) | $5.86 Million | -145.33% | 0.68x | $12.96 Million |
| IDORSIA AG (19T) | $104.20 Million | -608.99% | 13.23x | $582.75 Million |
| 1S90 (1S90) | $10.78 Million | -2319.92% | 31.35x | $54.21 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.28 Million |
| 25K0 (25K0) | $-79.67 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $508.00K | -2193.11% | 12.24x | $9.80 Million |
| Intervacc AB (publ) (2E9) | $308.25 Million | -9.53% | 0.07x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $3.03 Million | -558.03% | 2.82x | $9.20 Million |
| GNI Group Ltd (3G6) | $13.10 Billion | 1.39% | 0.57x | $772.60 Million |